Expand your biomarker strategy with NULISA™

We now offer NULISAseq™ CNS proteomics alongside our sFIDA oligomer quantification to support your biomarker-driven CNS research and clinical development with highly sensitive, multiplex pathway analysis in plasma and CSF.

Powered by Alamar Biosciences’ NULISA™ platform and combined with attyloid’s scientific expertise in CNS biomarker strategy, we advance your translational drug development.

Interested in integrating NULISA™ into your study?

Why integrate NULISA™ into your biomarker strategy?

NULISA™ enables highly sensitive multiplex biomarker profiling to uncover biological changes across a broad range of CNS-relevant pathways, helping you to generate deeper insight from minimal sample volumes.

Attomolar sensitivity

Detect ultra-low abundance biomarkers beyond the sensitivity range of conventional immunoassays.

Minimal sample input

Generate comprehensive biomarker profiling from low plasma or CSF sample volumes compatible with precious clinical specimens.

Translational CNS focus

Panels are specifically designed for neurodegenerative and CNS disease research applications.

Integrated biomarker strategies

Combine broad proteomic profiling with pathology-specific sFIDA oligomer measurements for a more comprehensive understanding of disease biology and drug response.

Broad biological               insights

Capture biomarker changes across multiple interconnected CNS disease pathways within a single analysis.

Biomarker discovery

Reveal unexpected biological signals, emerging biomarker patterns, and treatment-related changes beyond predefined hypotheses.

Available NULISA™ panels

Choose from validated CNS-focused biomarker panels designed for discovery, translational, and clinical research applications.

NULISAseq™ CNS Disease 120

Core CNS biomarker profiling panel

NULISAseq™ Neuro 220

Expanded CNS and neurodegeneration coverage

NULISAseq™ Mouse Panel

Preclinical translational biomarker profiling

NULISAqpcr™ AD 5-PLEX

Quantitative Alzheimer’s disease biomarker panel

Why work with attyloid?

At attyloid, NULISA™ is more than a proteomics service: it is a broader approach to translational CNS biomarker strategies. We combine ultra-sensitive biomarker technologies with scientific expertise in CNS pathology, streamlined workflows, and clinical study support.

We are providing:

  • Biomarker expertise from preclinical to clinical development

  • Experience supporting exploratory biomarker endpoints in CNS disease studies

  • Scientific interpretation in the context of disease and pathology

  • Streamlined workflows with consistent documentation

  • Dedicated support for study design, sample logistics, and data interpretation

Are you interested to know how NULISA™ can be implemented in your biomarker strategy?